Soleimani Samarkhazan Hamed, Zehtabcheh Sara, Peyvasteh Sajjad, Mohammadi Mohammad Hossein
Student Research Committee, Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, 61357-15794, Tehran, Iran.
Mol Biol Rep. 2025 May 16;52(1):464. doi: 10.1007/s11033-025-10527-x.
Leukemia, characterized by a heterogeneous spectrum of malignancies arising from the clonal expansion of hematopoietic progenitor cells, continues to represent a significant challenge within the field of oncology. Notwithstanding advancements in diagnostic techniques, therapeutic strategies, and prognostic tools, the complexities surrounding the pathogenesis of leukemia and its diverse clinical manifestations highlight the imperative need for the identification of novel biomarkers aimed at improving patient outcomes. The C-type lectin-like molecule-1 (CLL-1) has recently gained recognition as a particularly promising and appealing therapeutic target within the realm of leukemia. This cell surface receptor is characterized by an exceptionally high expression level on acute myeloid leukemia (AML) blasts. The consistent presence of CLL-1 on these cells not only emphasizes its prospective utility as a therapeutic target but also positions it as an optimal candidate for the surveillance of minimal residual disease (MRD). Furthermore, CLL-1 showcases innovative potential for the formulation of new immunotherapeutic strategies designed to combat leukemia. This narrative review aims to explore the structure, function, and diverse expression patterns of CLL-1 in relation to leukemia, thereby offering critical insights into its pivotal role in the disease's pathogenesis and its potential ramifications for treatment. The investigation of CLL-1 as a feasible target for diagnostic purposes, MRD monitoring, and the creation of novel immunotherapy strategies heralds the commencement of new and promising pathways for therapeutic approaches employed in the management of leukemia. A comprehensive understanding of the complex interplay between CLL-1 and the pathogenesis of leukemia will undeniably contribute to the design and advancement of more targeted and efficacious therapeutic interventions.
白血病是由造血祖细胞的克隆性扩增引起的一系列异质性恶性肿瘤，在肿瘤学领域仍然是一项重大挑战。尽管在诊断技术、治疗策略和预后工具方面取得了进展，但白血病发病机制及其多样临床表现的复杂性凸显了识别旨在改善患者预后的新型生物标志物的迫切需求。C型凝集素样分子-1（CLL-1）最近在白血病领域被公认为是一个特别有前景且有吸引力的治疗靶点。这种细胞表面受体在急性髓系白血病（AML）原始细胞上具有极高的表达水平。这些细胞上持续存在的CLL-1不仅强调了其作为治疗靶点的潜在效用，还使其成为监测微小残留病（MRD）的最佳候选者。此外，CLL-1在设计对抗白血病的新免疫治疗策略方面展现出创新潜力。这篇叙述性综述旨在探讨CLL-1与白血病相关的结构、功能和多样表达模式，从而深入了解其在疾病发病机制中的关键作用及其对治疗的潜在影响。将CLL-1作为诊断、MRD监测以及创建新型免疫治疗策略的可行靶点进行研究，预示着白血病治疗方法新的、有前景的途径的开启。全面了解CLL-1与白血病发病机制之间的复杂相互作用无疑将有助于设计和推进更具针对性和有效性的治疗干预措施。
